Peptides / Brain and mood

Mixture

Cerebrolysin

Approved in Austria, Russia +9

Cerebrolysin is a mix of small peptides and amino acids from pig brain, approved as a medicine in Austria, 8 other EU countries and Russia, but not by the FDA or EMA. Studies in people tested it on brain protection, memory and physical function. PepBank shows 727 results on Cerebrolysin from 176 studies in people, and 1,054 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Porcine brain peptide hydrolysate

Evidence level: Some studies in people727 of 1,781 results come from studies in people.

Results in people

727

41% of 1,781 results

Results in animals

864

49% of 1,781 results

Results in lab cells

190

11% of 1,781 results

From computer models

0% of 1,781 results

Overview

Cerebrolysin at a glance

What it is	Mixture
Approval	Approved nationally in 11 countries
In sport	Status unknown
Studies	442 studies with results. 372 of them gave Cerebrolysin, with 1,781 results. 727 in people864 in animals190 in lab cells
Best study in people	Randomized controlled trial with 1,070 people (2012)
Clinical trials	41 registered: 9 active or planned, 3 with posted results
Community use	Community cognitive use

The science

What is Cerebrolysin?

Porcine brain peptide and amino-acid mixture used as a prescription neurological product in some countries.

1,781

Study results in PepBank

The history of Cerebrolysin

1973
The oldest paper on Cerebrolysin in PepBank is from 1973.
2005October
A registered trial of Cerebrolysin started (NCT00840671).

Cerebrolysin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Structure

Cerebrolysin is a mixture, with no ring, no changed amino acids.

Development

EVER Neuro Pharma. Highest phase: past the trial stage (see status).

See charge, composition and 3D structure on the Scientific page

The evidence

What Cerebrolysin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people727 of 1,781 results come from studies in people.

Brain and nerves

684 results · 179 in people · 419 animal · 86 lab

In stroke patients, adding Cerebrolysin to Alteplase reduced symptomatic brain bleeding compared with Alteplase and baseline therapy alone. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2023

Top results

In stroke patients, adding Cerebrolysin to Alteplase reduced symptomatic brain bleeding compared with Alteplase and baseline therapy alone. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2023)
In geriatric patients, CNV amplitude changes favored cerebrolysin plus multivitamins over multivitamins alone. (Archives of gerontology and geriatrics, 1990)
In children with developmental dysphasia, parents reported less hyperactivity after cerebrolysin treatment. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013)

Memory and thinking

265 results · 172 in people · 93 animal

In vascular dementia, Cerebrolysin improved cognition more than placebo at week 24. Journal of stroke and cerebrovascular diseases, 2011

Top results

In vascular dementia, Cerebrolysin improved cognition more than placebo at week 24. (Journal of stroke and cerebrovascular diseases, 2011)
In Alzheimer's disease, cognitive effects did not differ significantly between Cerebrolysin plus donepezil and donepezil alone. (Current Alzheimer research, 2011)
In patients with Alzheimer's disease, Cerebrolysin improved cognitive scores more than placebo. (Journal of the American Geriatrics Society, 2000)

Daily life and fitness

147 results · 104 in people · 43 animal

In patients with acute ischemic stroke, Cerebrolysin did not significantly improve the combined functional endpoint compared with placebo. Stroke, 2012

Top results

In patients with acute ischemic stroke, Cerebrolysin did not significantly improve the combined functional endpoint compared with placebo. (Stroke, 2012)
In patients with Alzheimer's disease, Cerebrolysin did not significantly improve daily activities compared with placebo. (Journal of the American Geriatrics Society, 2000)
In stroke patients, Cerebrolysin did not significantly improve patient satisfaction compared with placebo. (Journal of medicine and life, 2017)

Overall treatment results

35 results · 35 in people

In vascular dementia, Cerebrolysin improved global clinical function more than placebo at week 24. Journal of stroke and cerebrovascular diseases, 2011

Top results

In vascular dementia, Cerebrolysin improved global clinical function more than placebo at week 24. (Journal of stroke and cerebrovascular diseases, 2011)
In Alzheimer's disease, Cerebrolysin plus donepezil improved global outcome more than donepezil alone. (Current Alzheimer research, 2011)
In moderate to moderately severe Alzheimer's disease, Cerebrolysin 60 ml improved global clinical function more than placebo at week 24. (European journal of neurology, 2011)

Immune system and inflammation

87 results · 32 in people · 39 animal · 16 lab

In stroke patients, cerebrolysin normalized impaired immune measures. Eksperimental'naia i klinicheskaia farmakologiia, 2008

Top results

In stroke patients, cerebrolysin normalized impaired immune measures. (Eksperimental'naia i klinicheskaia farmakologiia, 2008)
In four multiple sclerosis patients receiving cerebrolysin, MRI lesion counts decreased from 14 to 12. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2016)
In stroke patients, cerebrolysin normalized laboratory measures of inflammation. (Eksperimental'naia i klinicheskaia farmakologiia, 2008)

Survival and serious illness

33 results · 25 in people · 8 animal

In stroke patients, deaths before day 30 occurred in 4.3% with Cerebrolysin versus 8.7% with placebo. Neuropsychiatric disease and treatment, 2014

Top results

In stroke patients, deaths before day 30 occurred in 4.3% with Cerebrolysin versus 8.7% with placebo. (Neuropsychiatric disease and treatment, 2014)
In severe brain injury patients, Cerebrolysin use was not linked to a significant decrease in death probability versus controls. (Journal of clinical medicine, 2024)
In severe TBI patients, Cerebrolysin was linked to shorter hospital stays than standard decompression alone. (Clinical neurology and neurosurgery, 2022)

All 442 Cerebrolysin studies by area Open the Scientific page

Key Cerebrolysin studies

Studies in people come first, then studies in animals and in the lab.

People
Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial
Heiss et al. 2012 · Stroke · 1,070 people · cited by 83
4 results
People
Cerebrolysin as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study
Khasanova et al. 2023 · BMC neurology · 341 people · cited by 25
5 results
People
[Effects of simultaneous use of Cerebrolysin and alteplase on hemorrhagic transformation of brain infarction and functional outcome in stroke patients: CEREHETIS, a randomized, multicenter pilot trial]
Khasanova et al. 2023 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 341 people · cited by 5
4 results
People
Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial
Guekht et al. 2011 · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 242 people · cited by 36
6 results
People
Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial
Muresanu et al. 2020 · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 139 people · cited by 44
2 results

All 442 Cerebrolysin studies

Cerebrolysin clinical trials

ClinicalTrials.gov lists 41 trials of Cerebrolysin. 9 are active or planned, and 3 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia

Phase 4completed242 people

The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

Phase 4completed1,071 people

CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

Phase 4status unknown350 planned

All 18 Cerebrolysin trials

Status and safety

Is Cerebrolysin approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Not recorded

Status unknown.

Yes. Approved nationally in 11 countries. No FDA approval and no central EU authorisation (EMA). Status unknown.

Laws and labels change, so check the regulator for the current status.

Cerebrolysin side effects and safety

PepBank has 109 safety results from studies of Cerebrolysin. 96 of them come from studies in people.

Safety results from studies (109)

In stroke patients receiving alteplase and Cerebrolysin, no serious adverse events attributed to Cerebrolysin occurred. (BMC neurology, 2023)
In stroke patients receiving Cerebrolysin with Alteplase, no serious adverse events related to Cerebrolysin occurred. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2023)
In patients with aneurysmal subarachnoid hemorrhage, no severe adverse effects attributable to Cerebrolysin were observed. (BMC neurology, 2020)
In patients with Alzheimer's disease, adverse-event reporting was similar with Cerebrolysin and placebo. (European journal of neurology, 2006)
In vascular dementia, the study reported Cerebrolysin as safe and well tolerated. (Journal of stroke and cerebrovascular diseases, 2011)
In Alzheimer's disease patients, adverse events occurred in 64% with Cerebrolysin and 73% with placebo. (Journal of neural transmission, 2002)
In cervical myelopathy patients, Cerebrolysin patients improved or remained unchanged, whereas 7% of placebo patients deteriorated. (The spine journal, 2018)
In patients with acute stroke, adverse events occurred at similar frequencies with Cerebrolysin and placebo. (Journal of neural transmission, 2005)
In patients with moderate-severe brain injury, safety and tolerability were similar with Cerebrolysin and placebo. (Neurological sciences, 2020)
In moderate to moderately severe Alzheimer's disease, the study reported Cerebrolysin as safe and well tolerated. (European journal of neurology, 2011)
In stroke patients receiving alteplase, adverse events did not differ between Cerebrolysin and placebo groups. (International journal of stroke, 2013)
In patients with schizophrenia, neither cerebrolysin nor placebo groups had severe treatment adverse events, both with risperidone. (The Australian and New Zealand journal of psychiatry, 2012)
In stroke patients, safety measures did not differ significantly between Cerebrolysin and placebo. (Journal of medicine and life, 2017)
In stroke patients, adverse event rates did not differ significantly among Cerebrolysin, NBP, and placebo groups. (Experimental and therapeutic medicine, 2016)
In severe subacute stroke patients, no adverse events occurred in either the Cerebrolysin or placebo group. (Medicina, 2023)
In patients with Alzheimer's disease, no patients discontinued Cerebrolysin or placebo. (Journal of the American Geriatrics Society, 2000)
In acute ischemic stroke patients, no side effects of Cerebrolysin treatment were found. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010)
In stroke patients, deaths before day 30 occurred in 4.3% with Cerebrolysin versus 8.7% with placebo. (Neuropsychiatric disease and treatment, 2014)
In patients with small hypertensive intracranial hemorrhages, Cerebrolysin showed good tolerability without specific adverse-event data. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2009)
In stroke patients, Cerebrolysin was well tolerated, with safety comparable to placebo. (Stroke, 2016)
In patients with severe stroke, mortality by 90 days was lower with Cerebrolysin than with placebo. (Stroke, 2012)
In stroke patients, Cerebrolysin was safe and well tolerated. (Journal of medicine and life, 2017)
In stroke patients, Cerebrolysin triggered no paroxysmal EEG activity. (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2004)
In patients with poststroke aphasia, adverse event occurrence did not differ significantly between Cerebrolysin and placebo. (Stroke, 2025)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
30 mL daily	Human	human	intravenous infusion	10 days	Randomized trial in people · n = 1,070	Heiss 2012
30 mL/day	Human	human	Not reported	14 days	Randomized trial in people · n = 341	Khasanova 2023
30 mL	Human	human	intravenous	14 consecutive days	Randomized trial in people · n = 341	Khasanova 2023
20 mL	Human	human	Intravenous	Not reported	Randomized trial in people · n = 242	Guekht 2011
50 ml/day for 10 days, then two cycles of 10 ml/day for 10 days	Human	human	Not reported	Not reported	Randomized trial in people · n = 139	Muresanu 2020
10 ml	Human	human	Not reported	Not reported	Randomized trial in people · n = 133	Alvarez 2011
30 ml daily	Human	human	intravenous infusion	10 consecutive days	Randomized trial in people · n = 119	Lang 2013
30 mL over seven days followed by 10 mL until day 30	Human	human	Not reported	four weeks	Randomized trial in people · n = 100	Gharagozli 2017
30 mL once a day from Monday to Friday	Human	human	IV	4 weeks	Randomized trial in people · n = 53	Bae 2000
30 ml/day	Human	human	Not reported	14 days	Randomized trial in people · n = 50	Woo 2020
30 mL once daily	Human	human	intravenous infusion	5 days	Randomized trial in people · n = 32	Chen 2013
10 mL once daily, five days a week for the first month and three days a week for the next two months	Human	human	intravenous	1 month	Randomized trial in people · n = 20	Firstenfeld 2023
30 mL/d	Human	human	Not reported	21 days	Randomized trial in people	Muresanu 2016
10 mL	Human	human	intravenous	4 weeks	Randomized trial in people	Muresanu 2010
30 mL	Human	human	intravenous	4 weeks	Randomized trial in people	Muresanu 2010
0.1 mL/kg body weight every week	Human	human	injection	3 months	Randomized trial in people	Samir 2022
5 ml/d, 5d/week	Human	human	intramuscular	≥ 8-24 weeks	Randomized trial in people · n = 202	Hamed 2023
10, 30, 60 ml	Human	human	iv infusion	12 weeks	Randomized trial in people · n = 279	Alvarez 2006
30 mL	Human	human	intravenous	four weeks	Randomized trial in people · n = 192	Panisset 2002
50 mL/day	Human	human	IV	21 days	Randomized trial in people · n = 146	Ladurner 2005
30 ml	Human	human	infusion	four weeks, repeated after a two-months therapy-free interval	Randomized trial in people · n = 109	Ruether 2002
30 ml once daily Monday to Friday	Human	human	intravenous infusion	4 weeks	Randomized trial in people · n = 109	Xiao 2012
20 ml in 100 ml of saline solution, 20 infusions per annual course	Human	human	intravenous	3 years, annual 4-week courses	Randomized trial in people · n = 100	Ponomareva 2024
50 mL per day	Human	human	intravenous	10 days	Randomized trial in people · n = 96	Bajenaru 2010
60 ml	Human	human	IV infusion	twelve weeks	Randomized trial in people · n = 67	Alvarez 2011
30 ml	Human	human	IV infusion	twelve weeks	Randomized trial in people · n = 66	Alvarez 2011
10 ml	Human	human	IV infusion	twelve weeks	Randomized trial in people · n = 64	Alvarez 2011
30 ml/day	Human	human	Not reported	10 consecutive days	Randomized trial in people · n = 60	Stan 2017
0.1 mL/kg twice-weekly	Human	human	injections	5 weeks	Randomized trial in people · n = 60	Hassanein 2016
5 mL diluted in 100 mL normal saline over 30 minutes, once a day	Human	human	injection	21 days	Randomized trial in people · n = 60	Sharma 2022
15 ml daily (10 ml in the morning and 5 ml in the evening)	Human	human	intravenous	28 days	Randomized trial in people · n = 60	Vereshchagin 1991
0.1 cc/kg daily for 10 days then weekly	Human	human	intramuscular	4 months	Randomized trial in people · n = 50	Nasiri 2017
10 ml or 30 ml or 50 ml	Human	human	infusion	10 days	Randomized trial in people · n = 48	Funke 1998
50 ml	Human	human	Not reported	Not reported	Randomized trial in people · n = 47	Shamalov 2010
30 mL daily	Human	human	intravenous	10 days	Randomized trial in people · n = 46	Amiri-Nikpour 2014
20 ml	Human	human	Not reported	Not reported	Randomized trial in people · n = 40	Khabirov 2016
20.0 ml	Human	human	intravenous	4 weeks	Randomized trial in people · n = 40	Iznak 2016
30 ml	Human	human	intravenous	14 days	Randomized trial in people · n = 38	Maksimova 2009
50 ml/d	Human	human	Not reported	10 days	Randomized trial in people · n = 36	Skvortsova 2004
10 ml	Human	human	iv infusion	12 weeks	Randomized trial in people	Alvarez 2006

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

One wiki reports community cognitive use. Its regimen does not establish safety or efficacy. Government label dosing appears separately.

Reported routines and cautions

What people use it for

Community cognitive useS1

Reported regimens

Regimens that community sources report for Cerebrolysin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Community cognitive use	intramuscular	5 mL per dose	once daily	20 days, followed by a 1 to 2 month break	Single wiki source. The wiki contains supplier links and does not identify individual community reports.	S1
Registered dementia regimenOfficial label dosing of an approved product	injection or infusion	5 to 30 mL per dose	Not stated	Not stated	single source	S2

Community sources

S1Cerebrolysin community protocols (opens in a new tab)www.peptideprotocolwiki.com
S2North Macedonia registered medicine information (opens in a new tab)lekovi.zdravstvo.gov.mk

Gaps

The government registry gives no dose frequency or treatment duration. The wiki does not identify individual reports for its community regimen. Affiliate status remains unconfirmed.

Questions and more

Ask a question about Cerebrolysin

The answer links to every study it uses.

What does the evidence say about Cerebrolysin?Is Cerebrolysin tested in people?Compare with Delta sleep-inducing peptide (DSIP)Compare with Semax

Sources

Database: PepBank data for Cerebrolysin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about Cerebrolysin

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Cerebrolysin

Approved in Austria, Russia +9

Also known as Porcine brain peptide hydrolysate

What it is

Mixture

Approval

Approved nationally in 11 countries

In sport

Status unknown

Studies

442 studies with results. 372 of them gave Cerebrolysin, with 1,781 results.
727 in people864 in animals190 in lab cells

Best study in people

Randomized controlled trial with 1,070 people (2012)

Clinical trials

41 registered: 9 active or planned, 3 with posted results

Community use

Community cognitive use

Dose as reported

Class

Species

Route

Duration

Design

Source

30 mL daily

Human

human

intravenous infusion

10 days

Randomized trial in people · n = 1,070

Heiss 2012

30 mL/day

Human

human

Not reported

14 days

Randomized trial in people · n = 341

Khasanova 2023

30 mL

Human

human

intravenous

14 consecutive days

Randomized trial in people · n = 341

Khasanova 2023

20 mL

Human

human

Intravenous

Not reported

Randomized trial in people · n = 242

Guekht 2011

50 ml/day for 10 days, then two cycles of 10 ml/day for 10 days

Human

human

Not reported

Randomized trial in people · n = 139

Muresanu 2020

10 ml

Human

human

Not reported

Randomized trial in people · n = 133

Alvarez 2011

30 ml daily

Human

human

intravenous infusion

10 consecutive days

Randomized trial in people · n = 119

Lang 2013

30 mL over seven days followed by 10 mL until day 30

Human

human

Not reported

four weeks

Randomized trial in people · n = 100

Gharagozli 2017

30 mL once a day from Monday to Friday

Human

human

4 weeks

Randomized trial in people · n = 53

Bae 2000

30 ml/day

Human

human

Not reported

14 days

Randomized trial in people · n = 50

Woo 2020

30 mL once daily

Human

human

intravenous infusion

5 days

Randomized trial in people · n = 32

Chen 2013

10 mL once daily, five days a week for the first month and three days a week for the next two months

Human

human

intravenous

1 month

Randomized trial in people · n = 20

Firstenfeld 2023

30 mL/d

Human

human

Not reported

21 days

Randomized trial in people

Muresanu 2016

10 mL

Human

human

intravenous

4 weeks

Randomized trial in people

Muresanu 2010

30 mL

Human

human

intravenous

4 weeks

Randomized trial in people

Muresanu 2010

0.1 mL/kg body weight every week

Human

human

injection

3 months

Randomized trial in people

Samir 2022

5 ml/d, 5d/week

Human

human

intramuscular

≥ 8-24 weeks

Randomized trial in people · n = 202

Hamed 2023

10, 30, 60 ml

Human

human

iv infusion

12 weeks

Randomized trial in people · n = 279

Alvarez 2006

30 mL

Human

human

intravenous

four weeks

Randomized trial in people · n = 192

Panisset 2002

50 mL/day

Human

human

21 days

Randomized trial in people · n = 146

Ladurner 2005

30 ml

Human

human

infusion

four weeks, repeated after a two-months therapy-free interval

Randomized trial in people · n = 109

Ruether 2002

30 ml once daily Monday to Friday

Human

human

intravenous infusion

4 weeks

Randomized trial in people · n = 109

Xiao 2012

20 ml in 100 ml of saline solution, 20 infusions per annual course

Human

human

intravenous

3 years, annual 4-week courses

Randomized trial in people · n = 100

Ponomareva 2024

50 mL per day

Human

human

intravenous

10 days

Randomized trial in people · n = 96

Bajenaru 2010

60 ml

Human

human

IV infusion

twelve weeks

Randomized trial in people · n = 67

Alvarez 2011

30 ml

Human

human

IV infusion

twelve weeks

Randomized trial in people · n = 66

Alvarez 2011

10 ml

Human

human

IV infusion

twelve weeks

Randomized trial in people · n = 64

Alvarez 2011

30 ml/day

Human

human

Not reported

10 consecutive days

Randomized trial in people · n = 60

Stan 2017

0.1 mL/kg twice-weekly

Human

human

injections

5 weeks

Randomized trial in people · n = 60

Hassanein 2016

5 mL diluted in 100 mL normal saline over 30 minutes, once a day

Human

human

injection

21 days

Randomized trial in people · n = 60

Sharma 2022

15 ml daily (10 ml in the morning and 5 ml in the evening)

Human

human

intravenous

28 days

Randomized trial in people · n = 60

Vereshchagin 1991

0.1 cc/kg daily for 10 days then weekly

Human

human

intramuscular

4 months

Randomized trial in people · n = 50

Nasiri 2017

10 ml or 30 ml or 50 ml

Human

human

infusion

10 days

Randomized trial in people · n = 48

Funke 1998

50 ml

Human

human

Not reported

Randomized trial in people · n = 47

Shamalov 2010

30 mL daily

Human

human

intravenous

10 days

Randomized trial in people · n = 46

Amiri-Nikpour 2014

20 ml

Human

human

Not reported

Randomized trial in people · n = 40

Khabirov 2016

20.0 ml

Human

human

intravenous

4 weeks

Randomized trial in people · n = 40

Iznak 2016

30 ml

Human

human

intravenous

14 days

Randomized trial in people · n = 38

Maksimova 2009

50 ml/d

Human

human

Not reported

10 days

Randomized trial in people · n = 36

Skvortsova 2004

10 ml

Human

human

iv infusion

12 weeks

Randomized trial in people

Alvarez 2006

Context

Route

Amount

How often

How long

Agreement

Sources

Community cognitive use

intramuscular

5 mL per dose

once daily

20 days, followed by a 1 to 2 month break

Single wiki source. The wiki contains supplier links and does not identify individual community reports.

Registered dementia regimenOfficial label dosing of an approved product

injection or infusion

5 to 30 mL per dose

Not stated

single source

Cerebrolysin

Cerebrolysin at a glance

What is Cerebrolysin?

The history of Cerebrolysin

Cerebrolysin structure and chemistry

What Cerebrolysin studies show

Brain and nerves

Memory and thinking

Daily life and fitness

Overall treatment results

Immune system and inflammation

Survival and serious illness

Key Cerebrolysin studies

Cerebrolysin clinical trials

Is Cerebrolysin approved?

Cerebrolysin side effects and safety

How people use it

What people use it for

Reported regimens

Community sources

Ask a question about Cerebrolysin

Related peptides

Sources

Cerebrolysin

Cerebrolysin at a glance

What is Cerebrolysin?

The history of Cerebrolysin

Cerebrolysin structure and chemistry

What Cerebrolysin studies show

Brain and nerves

Memory and thinking

Daily life and fitness

Overall treatment results

Immune system and inflammation

Survival and serious illness

Key Cerebrolysin studies

Cerebrolysin clinical trials

Is Cerebrolysin approved?

Cerebrolysin side effects and safety

How people use it

What people use it for

Reported regimens

Community sources

Ask a question about Cerebrolysin

Related peptides

Sources